JOURNAL OF CRITICAL REVIEWS

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

SYMPTOMS OF CLASSICAL MCAD DEFICIENCY, VARIANT MCAD DEFICIENCY AS WELL AS SILENT MCAD DEFICIENCY, DIAGNOSIS OF MCAD DEFICIENCY, DIFFERENTIAL DIAGNOSIS OF MCAD DEFICIENCY AND TREATMENT AS WELL AS MANAGEMENT OF MCAD DEFICIENCY

Vinayasree.C[1],Mohan naidu.K[2] ,Muralinath.E[2] , Pavan Eswar Reddy.K[3] ,Pavan kumar.K[4] Guruprasad.M[5] , Sravani pragna.K[2]

[1]College of Veterinary Science, Korutla, PVNRTVU, Telengana, India
[2]College of Veterinary Science, Proddatur, Andhra Pradesh, India
[3]Shantiram Medical College, Nandyal, Andhra Pradesh, India
[4]Rajiv Gandhi Institute of Medical sciences (RIMS), Cuddapah, Andhra Pradesh, India.
[5]Vaishnavi Microbial Pvt. Ltd. Hyderabad. India.
Corresponding Author: muralinathennamuri@gmail.com

Abstract:-
Medium - chain acetyl - CoA dehydrogenase (MCAD) deficiency ia a rare inherited metabolic disorder that shows its influence on the bodys capability to breakdown fatty acids for energy. The symptoms of classical MCAD deficiency typically manifest especially during infancy or early childhood. Variant MCAD deficiency is happened by mutations in the ACADM gene. Symptoms of variant MCAD deficiency are hypoglycemia, vomiting, lethargy, encephalopathy and liver dysfunction. Silent MCAD deficiency is also known as silent medium - chain acyl CoA dehydrogenase deficiency. Symptoms of silent MCAD deficiency are hypoglycemia, fatigue, poor weight gain or growth, encephalopathy, Reye-like syndrome, genetic testing, neuro imaging and Electro encephalogram (EEG) estimations can assist in differentiating epilepsy from MCAD deficiency. Finally it is concluded that treatment is linked to carefully planned diet, carbohydrate - rich diet, medium - chain triglyceride (MCT) oil and genetic counselling.

Keywords:-
Mrdium - chain acyl-CoA dehydrogenase, hypoglycemia, autosomal recessive disorder, vomiting, hepatomegaly, muscle weakness, metabolic disorder, fatigue, irritability, dizziness, confusion, loss of consciousness, fasting, illness, encephalopathy, confusion, seizures, abnormal behaviour, coma, metabolic acidosis, multi - organ failure, excessive tiredness, brain swelling (encephalopathy), acyl carnitine, long - chain acyl - CoA dehydrogenase (LCAD) deficiency, Short - chain acyl - CoA dehydrogenase (SCAD) deficiency, carnitine palmitoyl trnsferase (CPT) deficiency, propionic acedemia, methyl melonic acidemia, electro encephalo gram (EEG), planned diet, MCT oil and specific markers regarding fatty acid metabolism.

Introduction:

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a rare inherited metabolic disorder that influences the body's ability to break down fatty acids for energy. This condition

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

results in potentially life-threatening episodes of low blood sugar (hypoglycemia) and other metabolic disturbances. In this article, we have given information about causes, symptoms, diagnosis, and management of MCAD deficiency.

Types of MCAD:
There are different types or variants of MCAD deficiency, which can vary in terms of their severity and clinical presentation. Here are some of the commonly recognized types:
1. Clasical MCAD deficiency
2. Varient MCAD deficiency
3. Silent MCAD deficiency

1. Classical MCAD deficiency:
Classical MCAD (Medium-Chain Acyl-CoA Dehydrogenase) deficiency, also known as MCADD, is a rare inherited metabolic disorder that affects the body's ability to break down certain types of fats termed as medium-chain fatty acids (MCFA). It occurs by a mutation in the ACADM gene, which leads to a deficiency or malfunctioning of the medium-chain acyl-CoA dehydrogenase enzyme.

MCADD is an autosomal recessive disorder, meaning that both copies of the ACADM gene must be affected for the condition to manifest. If an individual has only one affected copy, they are treated as carriers of the condition but do not typically show symptoms.

The deficiency In the medium-chain acyl-CoA dehydrogenase enzyme impairs the body's capability to change MCFA into energy. As a result, affected individuals may exhibit episodes of low blood sugar (hypoglycemia) and the collection of harmful substances termed aS medium-chain fatty acids in their tissues and organs.

Symptoms of classical MCAD deficiency:
The symptoms of classical MCAD deficiency typically manifest particularly during infancy or early childhood, often triggered by periods of fasting or illness. Here are some common symptoms related to classical MCAD deficiency:

Repeated episodes of hypoglycemia (low blood sugar): This is one of the hallmark symptoms of MCAD deficiency. It can lead to symptoms namely lethargy, irritability, sweating, and pale skin.

Vomiting and poor feeding: Infants with MCAD deficiency may exhibit difficulties feeding and may expertise frequent episodes of vomiting, especially during periods of fasting or illness.

Lethargy and fatigue: Individuals with MCAD deficiency may seem to be excessively tired, weak, or lethargic. They may lack energy and have difficulty engaging in physical activity.

Enlarged liver: MCAD deficiency leads to the occurrence of hepatomegaly (enlargement of liver). This may be noticeable particularly during a physical examination.

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

Muscle weakness: Some individuals with MCAD deficiency may experience muscle weakness or have trouble with muscle coordination.
Seizures: In severe cases or during metabolic crises, individuals with MCAD deficiency may lead to the occurrence of seizures.

2. Variant MCAD deficiency:
Variant MCAD (Medium-Chain Acyl-CoA Dehydrogenase) Deficiency, also termed as MCADD, is an inherited metabolic disorder that influences the body's capability to break down certain types of fats for energy. It is happened by mutations in the ACADM gene, which gives instructions for producing an enzyme termed as medium-chain acyl-CoA dehydrogenase.

In individuals with variant MCAD deficiency, the enzyme medium-chain acyl-CoA dehydrogenase is either absent or not functioning in a proper manner, leading to a reduced capability to metabolize medium-chain fatty acids. These fatty acids behave as source of energy, especially during periods of fasting or increased energy demands.

Symptoms of variant MCAD deficiency:
Symptoms of variant MCAD deficiency can vary in severity and may manifest in different ways. Here are some common symptoms related to this condition:

Hypoglycemia (low blood sugar):
This is one of the hallmark symptoms of MCAD deficiency. It can lead to the symptoms namely fatigue, irritability, dizziness, confusion, and even loss of consciousness.

Repeated episodes of vomiting:
Individuals with MCAD deficiency may experience recurrent episodes of vomiting, especially during times of fasting, illness, or prolonged periods without food intake.

Lethargy and Weakness:
People with MCAD deficiency may feel excessively tired, weak, or lack of energy due to the body's inability to efficiently change stored fats into energy.

Encephalopathy:
In severe cases, MCAD deficiency results in encephalopathy, which is manifested by confusion, seizures, abnormal behavior, and coma. This is a medical emergency and needs immediate attention.

Liver Dysfunction:
Some individuals may develop liver problems, namely hepatomegaly (enlarged liver) or enhanced liver enzymes.

Failure to Thrive:
Infants with MCAD deficiency may have difficulty gaining weight and growing at a normal rate.

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

Metabolic Crisis:
Without proper management, MCAD deficiency results in life-threatening metabolic crises, which are manifested by severe symptoms namely metabolic acidosis, hypoketotic hypoglycemia, liver dysfunction, and multi-organ failure.

3. Silent MCAD deficiency:
Silent MCAD deficiency, also termed as silent medium-chain acyl-CoA dehydrogenase deficiency, is a rare genetic disorder that influences the body's capability to break down certain types of fats for energy. It is an autosomal recessive disorder, indicating that both copies of the responsible gene must be mutated for the condition to be apparent.

MCAD refers to medium-chain acyl-CoA dehydrogenase, which is an enzyme participated in the breakdown of medium-chain fatty acids. In individuals with silent MCAD deficiency, there is a partial or complete deficiency of this enzyme, results in difficulties regarding processing these specific types of fats.

The term "silent" In silent MCAD deficiency refers to the fact that affected individuals typically do not display any symptoms or signs of the condition under normal circumstances. This is in contrast to classical MCAD deficiency, which is characterized by potentially life-threatening episodes of low blood sugar (hypoglycemia), lethargy, vomiting, and liver dysfunction.

Silent MCAD deficiency is usually discovered incidentally if affected individuals undergo metabolic testing for other reasons, namely pre-surgical screening or newborn screening. While individuals with silent MCAD deficiency normally do not experience symptoms, they still carry the genetic mutation and exhibit a risk of passing it on to their offspring.

Symptoms of Silent MCAD deficiency:
Hypoglycemia:
Low blood sugar levels can occuhappen, particularly during periods of fasting, illness, or prolonged physical activity.

Fatigue:
Individuals with silent MCAD deficiency may feel excessive tiredness and a deficiency of energy.

Repeated vomiting:
Episodes of vomiting may occur, especially during times of metabolic stress.

Poor weight gain or growth:
Infants and young children with silent MCAD deficiency may exhibit difficulty gaining weight or growing at a normal rate.

Encephalopathy:

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

In rare cases, individuals may show neurological symptoms, namely confusion, seizures, or coma.

Reye-like syndrome:
A rare complication manifested by liver dysfunction and brain swelling (encephalopathy), which can result in neurological impairment or even death.

Diagnosis:
MCAD deficiency can be challenging to diagnose, as its symptoms can mimic other common childhood illnesses. Whatever it may be, early detection is critical to prevent life-threatening complications. Diagnostic approaches include:

Newborn Screening:
Many countries have incorporated MCAD deficiency into their newborn screening programs, permitting for early identification of affected infants.

Acylcarnitine Profile:
Blood tests that measure the levels of specific acylcarnitines can assist in identifying abnormalities associated with MCAD deficiency.

Genetic Testing:
Analysis of the ACADM gene can confirm the diagnosis by recognizing the presence of pathogenic mutations.

Differential diagnosis of MCAD Deficiency:
It is important to consider other conditions with similar symptoms when performing a differential diagnosis. Here are some conditions that can be considered in the differential diagnosis of MCAD deficiency:

Other fatty acid oxidation disorders:
Conditions namely long-chain acyl-CoA dehydrogenase (LCAD) deficiency, short-chain acyl-CoA dehydrogenase (SCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, and carnitine palmitoyl transferase (CPT) deficiencies can present with similar symptoms to MCAD deficiency. Genetic testing and specific enzyme analysis can assist in differentiating between these disorders.

Hypoglycemia:
Low blood sugar levels can cause symptoms similar to MCAD deficiency. Conditions namely glycogen storage diseases, including type I (von Gierke disease), type III (Cori disease), and type IV (Andersen disease), can cause hypoglycemia because of impaired glycogen metabolism.

Reye syndrome:
This is a rare but serious condition that primarily influences children. It is happened by acute liver dysfunction and encephalopathy, and can present with symptoms namely vomiting,

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

lethargy, seizures, and liver abnormalities. Reye syndrome is often linked to recent viral infections and the use of aspirin.

Sepsis:
Severe infections can lead to metabolic derangements, along with hypoglycemia and metabolic acidosis, which can mimic the symptoms of MCAD deficiency. A thorough evaluation for infection, along with appropriate laboratory tests, can assist rule out sepsis.

Other causes of metabolic acidosis:
Conditions namely organic acidemias (e.g., propionic acidemia, methylmalonic acidemia) and urea cycle disorders lead to the occurrence of metabolic acidosis and other systemic symptoms, resembling MCAD deficiency. Specific metabolic testing can assist in the diagnosis.

Epilepsy:
Some forms of epilepsy, especially those associated with mitochondrial disorders or certain inborn errors of metabolism, can present with symptoms similar to MCAD deficiency. Genetic testing, neuroimaging, and electroencephalogram (EEG) evaluations can help differentiate epilepsy from MCAD deficiency.

Treatment and management:
The treatment and management of MCAD deficiency primarily are related to dietary modifications, close monitoring, and emergency preparedness. Here are some key aspects:

1. **Medical Team:**
It is essential to consult with a metabolic specialist or a physician experienced in managing inborn errors of metabolism to ensure appropriate diagnosis, treatment, and ongoing care.

2. **Dietary Modifications:**
The mainstay of treatment for MCAD deficiency is linked to carefully planned diet. The goal is to regulate stable blood sugar levels and obstruct the buildup of toxic byproducts. Key dietary recommendations include:

Frequent meals:
Individuals with MCAD deficiency need to consume small, frequent meals throughout the day, typically every 2-4 hours, to escape from prolonged fasting periods.

Avoidance of fasting:
Prolonged fasting, including skipping meals or overnight fasting, should be strictly avoided, as it can lead to the occurrence of metabolic crises.

Carbohydrate-rich diet:
A diet that is relatively higher in carbohydrates and lower in fats is recommended. Complex carbohydrates namely whole grains, fruits, and vegetables are selected over simple sugars.

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

Medium-chain triglyceride (MCT) oil:
MCT oil can be added in the diet as it bypasses the defective enzyme and provides a readily available source of energy. Whatever it may be, the use of MCT oil should be carefully monitored and adjusted, as excessive intake can be harmful.

Emergency carbohydrates:
Rapidly digestible carbohydrates namely glucose gel or juice should be readily available particularly in case of illness, prolonged exercise, or other situations that might enhance energy demands.

1. Regular Monitoring:
Close monitoring of the individual's health and metabolic status is critical. This typically involves regular check-ups, blood tests to measure blood sugar levels, and monitoring of specific markers regarding fatty acid metabolism.

2. Emergency Preparedness:
It is essential to be prepared for metabolic crises, which can be triggered particularly by illnesses, prolonged fasting, or other stressors. Emergency plans should be incorporated in collaboration with the medical team and may involve specific guidelines for enhancing carbohydrate intake during illness, ensuring easy access to emergency carbohydrates, and establishing clear protocols for seeking medical attention.

3. Genetic Counseling:
MCAD deficiency is an inherited condition, so genetic counseling is preferred for affected individuals and their families. This can assist in understanding the risk of passing on the condition to future generations and make informed family planning decisions.

Conclusion:
MCAD deficiency is a rare metabolic disorder that needs early recognition and management to obstruct potentially life-threatening complications. With an advances in newborn screening and enhanced awareness, affected individuals can receive timely interventions and lead fulfilling lives. Ongoing research and improved understanding of the underlying mechanisms of MCAD deficiency result in further advancements in diagnosis, treatment, and quality of life for those affected by this condition.

References & Further Reading

- Abulí A, Boada M, Rodríguez-Santiago B, Coroleu B, Veiga A, Armengol L, Barri PN, Pérez-Jurado LA, Estivill X. NGS-based assay for the identification of individuals carrying recessive genetic mutations in reproductive medicine. Hum Mutat. 2016;37:516–23. [PubMed]
- Ahrens-Nicklas RC, Pyle LC, Ficicioglu C. Morbidity and mortality among exclusively breastfed neonates with medium-chain acyl-CoA dehydrogenase deficiency. Genet Med. 2016;18:1315–9. [PMC free article] [PubMed]

ISSN- 2394-5125 VOL 10, ISSUE 04, 2023

- Aksglaede L, Christensen M, Olesen JH, Duno M, Olsen RK, Andresen BS, Hougaard DM, Lund AM. Abnormal newborn screening in a healthy infant of a mother with undiagnosed medium-chain Acyl-CoA dehydrogenase deficiency. JIMD Rep. 2015;23:67–70. [PMC free article] [PubMed]
- Albers S, Levy HL, Irons M, Strauss AW, Marsden D. Compound heterozygosity in four asymptomatic siblings with medium-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2001;24:417–8. [PubMed]
- Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for fatty acid oxidation and carnitine disorders. Pediatr Emerg Care. 2017;33:296–301. [PubMed]
- Alfardan J, Mohsen AW, Copeland S, Ellison J, Keppen-Davis L, Rohrbach M, Powell BR, Gillis J, Matern D, Kant J, Vockley J. Characterization of new ACADSB gene sequence mutations and clinical implications in patients with 2-methylbutyrylglycinuria identified by newborn screening. Mol Genet Metab. 2010;100:333–8. [PMC free article] [PubMed]
- Al-Hassnan ZN, Imtiaz F, Al-Amoudi M, Rahbeeni Z, Al-Sayed M, Al-Owain M, Al-Zaidan H, Al-Odaib A, Rashed MS. Medium-chain acyl-CoA dehydrogenase deficiency in Saudi Arabia: incidence, genotype, and preventive implications. J Inherit Metab Dis. 2010;33 Suppl 3:S263–7. [PubMed]
- Anderson S, Botti C, Li B, Millonig JH, Lyon E, Millson A, Karabin SS, Brooks SS. Medium chain acyl-CoA dehydrogenase deficiency detected among Hispanics by New Jersey newborn screening. Am J Med Genet A. 2012;158A:2100–5. [PubMed]
- Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, Udvari S, Bross P, Knudsen I, Banas R, Chace DH, Engel P, Naylor EW, Gregersen N. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68:1408–18. [PMC free article] [PubMed]
- Andresen BS, Lund AM, Hougaard DM, Christensen E, Gahrn B, Christensen M, Bross P, Vested A, Simonsen H, Skogstrand K, Olpin S, Brandt NJ, Skovby F, Nørgaard-Pedersen B, Gregersen N. MCAD deficiency in Denmark. Mol Genet Metab. 2012;106:175–88. [PubMed]
- Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA, Erbe R, Devincentis E, Kronn D, Mofidi S, Wasserstein M, Pellegrino JE, Levy PA, Adams DJ, Nichols M, Caggana M. Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab. 2010;99:263–8. [PubMed]
- Bennett MJ, Rinaldo P, Millington DS, Tanaka K, Yokota I, Coates PM. Medium-chain acyl-CoA dehydrogenase deficiency: postmortem diagnosis in a case of sudden infant death and neonatal diagnosis of an affected sibling. Pediatr Pathol. 1991;11:889–95. [PubMed]